Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
The closing price of Immunocore Holdings plc ADR (NASDAQ: IMCR) was $58.10 for the day, down -0.62% from the previous closing price of $58.46. In other words, the price has decreased by -$0.62 from its previous closing price. On the day, 0.54 million shares were traded. IMCR stock price reached its highest trading level at $60.02 during the session, while it also had its lowest trading level at $57.6.
Ratios:
Our analysis of IMCR’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 3.77 and its Current Ratio is at 3.80. In the meantime, Its Debt-to-Equity ratio is 0.23 whereas as Long-Term Debt/Eq ratio is at 0.22.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Leerink Partners on Apr-30-24, initiated with a Outperform rating and assigned the stock a target price of $74.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Apr 01 ’24 when St Leger Tina Amber sold 4,375 shares for $64.06 per share. The transaction valued at 280,262 led to the insider holds 0 shares of the business.
Berman David M sold 36,509 shares of IMCR for $2,504,158 on Feb 28 ’24. The HEAD OF R&D now owns 0 shares after completing the transaction at $68.59 per share. On Feb 27 ’24, another insider, Berman David M, who serves as the HEAD OF R&D of the company, sold 54,938 shares for $70.86 each. As a result, the insider received 3,893,030 and left with 0 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IMCR now has a Market Capitalization of 2905354240 and an Enterprise Value of 2535983616. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.56 while its Price-to-Book (P/B) ratio in mrq is 7.88. Its current Enterprise Value per Revenue stands at 10.167 whereas that against EBITDA is -44.92.
Stock Price History:
The Beta on a monthly basis for IMCR is 0.92, which has changed by 0.009030938 over the last 52 weeks, in comparison to a change of 0.24191546 over the same period for the S&P500. Over the past 52 weeks, IMCR has reached a high of $76.98, while it has fallen to a 52-week low of $42.21. The 50-Day Moving Average of the stock is -6.96%, while the 200-Day Moving Average is calculated to be -2.53%.
Shares Statistics:
IMCR traded an average of 508.11K shares per day over the past three months and 469050 shares per day over the past ten days. A total of 49.73M shares are outstanding, with a floating share count of 48.78M. Insiders hold about 1.91% of the company’s shares, while institutions hold 74.06% stake in the company. Shares short for IMCR as of 1713139200 were 4088861 with a Short Ratio of 8.05, compared to 1710460800 on 4291197. Therefore, it implies a Short% of Shares Outstanding of 4088861 and a Short% of Float of 9.32.
Earnings Estimates
Its stock is currently analyzed by 16.0 different market analysts. On average, analysts expect EPS of -$0.36 for the current quarter, with a high estimate of -$0.1 and a low estimate of -$0.51, while EPS last year was -$0.43. The consensus estimate for the next quarter is -$0.39, with high estimates of -$0.16 and low estimates of -$0.48.
Analysts are recommending an EPS of between -$0.69 and -$2.57 for the fiscal current year, implying an average EPS of -$1.64. EPS for the following year is -$2.35, with 16.0 analysts recommending between -$0.98 and -$4.74.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 15 analysts. It ranges from a high estimate of $91.99M to a low estimate of $64.9M. As of the current estimate, Immunocore Holdings plc ADR’s year-ago sales were $54.93MFor the next quarter, 15 analysts are estimating revenue of $73.85M. There is a high estimate of $101.19M for the next quarter, whereas the lowest estimate is $68M.
A total of 17 analysts have provided revenue estimates for IMCR’s current fiscal year. The highest revenue estimate was $404.1M, while the lowest revenue estimate was $276.7M, resulting in an average revenue estimate of $299.32M. In the same quarter a year ago, actual revenue was $249.43MBased on 16 analysts’ estimates, the company’s revenue will be $313.95M in the next fiscal year. The high estimate is $347.87M and the low estimate is $280.6M.
